# Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

> **NCT03167411** · PHASE1 · COMPLETED · sponsor: **Theracos** · enrollment: 20 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Bexagliflozin
- **DRUG:** Exenatide Injection

## Key facts

- **NCT ID:** NCT03167411
- **Lead sponsor:** Theracos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-24
- **Primary completion:** 2017-06-29
- **Final completion:** 2017-06-29
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167411, "Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03167411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*